Mostrar el registro sencillo del ítem
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
dc.contributor.author | Carrato, Alfredo | |
dc.contributor.author | Abad, Albert | |
dc.contributor.author | Massuti, Bartomeu | |
dc.contributor.author | Grávalos, Cristina | |
dc.contributor.author | Escudero, Pilar | |
dc.contributor.author | Longo-Muñoz, Federico | |
dc.contributor.author | Manzano, José-Luis | |
dc.contributor.author | Gómez, Auxiliadora | |
dc.contributor.author | Safont, María José | |
dc.contributor.author | Gallego, Javier | |
dc.contributor.author | García-Paredes, Beatriz | |
dc.contributor.author | Pericay, Carles | |
dc.contributor.author | Dueñas, Rosario | |
dc.contributor.author | Rivera, Fernando | |
dc.contributor.author | Losa, Ferrán | |
dc.contributor.author | Valladares Ayerbes, Manuel | |
dc.contributor.author | González, E | |
dc.contributor.author | Aranda, E | |
dc.contributor.author | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
dc.date.accessioned | 2017-09-15T08:17:13Z | |
dc.date.available | 2017-09-15T08:17:13Z | |
dc.date.issued | 2017-08 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/?term=28633089 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/9542 | |
dc.description.abstract | In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. However no trial has directly compared these combinations. Multicentre, open-label study in untreated patients ≥ 18 years with (WT)-KRAS mCRC and multiple or unresectable liver-limited disease (LLD) randomised to either Pmab-FOLFOX4 or Pmab-FOLFIRI. The primary end-point was objective response rate (ORR). Secondary end-points included liver metastases resection rate (R0 + R1), progression-free survival (PFS), overall survival (OS), adverse events and perioperative safety. Exploratory end-points were: response by RAS status, early tumour shrinkage (ETS) and depth of response (DpR) in WT-RAS patients. Data on 77 patients were analysed (38 Pmab-FOLFOX4; 39 Pmab-FOLFIRI; WT-RAS: 27/26, respectively). ORR was 74% with Pmab-FOLFOX4 and 67% with Pmab-FOLFIRI (WT-RAS: 78%/73%). Out of the above, 45% and 59% underwent surgical resection, respectively (WT-RAS: 37%/69%). The R0-R1 resection rate was 34%/46% (WT-RAS:26%/54%). Median PFS was 13/14 months (hazard ratio [HR] Pmab-FOLFIRI versus Pmab-FOLFOX4: 0.9; 95% confidence interval: [0.6-1.5]; WT-RAS:13/15; HR: 0.7 [0.4-1.3]). Median OS was 37/41 months (HR:1.0 [0.6-1.8]; WT-RAS: 39/49; HR:0.9 [0.4-1.9]). In WT-RAS patients with confirmed response, median DpR was 71%/66%, and 65%/77% of patients showed ETS ≥ 30%/ ≥ 20% at week 8, without significant differences between arms; these patients had longer median PFS and OS and higher resectability rates. Surgery was associated with longer survival. Perioperative and overall safety were similar, except for higher grade 3/4 neutropenia (40%/10%; p = 0.003) and neuropathy (13%/0%; p = 0.025) in the Pmab-FOLFOX4 arm. In patients with WT-KRAS mCRC and LLD, both first-line Pmab-FOLFOX4 and Pmab-FOLFIRI resulted in high ORR and ETS, allowing potentially curative resection. No significant differences in efficacy were observed between the two regimens. (clinicaltrials.gov:NCT00885885). | es |
dc.description.sponsorship | Amgen S.A. | es |
dc.language.iso | eng | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | Appetite | * |
dc.subject.mesh | Skin | * |
dc.subject.mesh | Neutropenia | * |
dc.subject.mesh | Fluorouracil | * |
dc.subject.mesh | Leucovorin | * |
dc.subject.mesh | Pruritus | * |
dc.subject.mesh | Asthenia | * |
dc.subject.mesh | Medical Oncology | * |
dc.subject.mesh | Colorectal Neoplasms | * |
dc.title | First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). | es |
dc.type | Artigo | es |
dc.rights.holder | Los autores | es |
dc.identifier.doi | 10.1016/j.ejca.2017.04.024 | |
dc.identifier.essn | 1879-0852 | |
dc.identifier.pmid | 28633089 | |
dc.journal.title | European journal of cancer (Oxford, England : 1990) | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña ::Oncoloxía médica | es |
dc.page.initial | 191 | es |
dc.page.final | 202 | es |
dc.relation.publisherversion | http://www.sciencedirect.com/science/article/pii/S0959804917309516?via%3Dihub | es |
dc.rights.accessRights | openAccess | es |
dc.subject.decs | fluorouracilo | * |
dc.subject.decs | prurito | * |
dc.subject.decs | piel | * |
dc.subject.decs | oncología médica | * |
dc.subject.decs | astenia | * |
dc.subject.decs | neutropenia | * |
dc.subject.decs | leucovorina | * |
dc.subject.decs | neoplasias colorrectales | * |
dc.subject.decs | apetito | * |
dc.subject.keyword | Panitumumab | es |
dc.subject.keyword | FOLFOX | es |
dc.subject.keyword | Cáncer colorrectal metastásico | es |
dc.typefides | Artigo Científico (inclue Orixinal, Orixinal breve, Revisión Sistemática e Meta-análisis) | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 81 | es |